Heptares eyes promise of the East as it seeks out new partnerships
This article was originally published in Scrip
Heptares Therapeutics has already established a solid link with Japan through its G-protein coupled receptor (GPCR) drug discovery collaboration with Takeda signed nearly a year ago, which seems to have piqued the attention of other potential partners in the country.
You may also be interested in...
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.